Stock AnalizKiniksa Pharmaceuticals International, plc KNSA
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Kiniksa Pharmaceuticals International, plc (KNSA) is a healthcare company listed in the US with a market value of about $7.6B. In the twelve months to September 30, 2026 it had revenue of $946M and net income of $110M, a net margin of 11.6%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is future growth (5/5); the weakest is value (0/5).
Key numbers: a P/E of 73.5, a price to free cash flow of 38.4, a 5-year average ROIC of -13%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 19% below the current price.
Score: 2.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $946M | $678M | $423M | $270M | $220M | $39M | — | — | — | — |
| Net income | $110M | $59M | -$43M | $14M | $183M | -$158M | -$161M | -$162M | -$103M | -$65M |
| Free cash flow | $197M | $136M | $25M | $13M | $6M | -$127M | -$137M | -$162M | -$86M | -$50M |
| EPS (diluted) | $1.31 | $0.75 | $-0.60 | $0.20 | $2.60 | $-2.30 | $-2.61 | $-2.99 | $-3.49 | $-35.85 |
| Net margin | 11.6% | 8.7% | -10.2% | 5.2% | 83.3% | -409.7% | — | — | — | — |
| ROIC | — | 8.9% | -8.0% | -4.4% | 1.9% | -64.8% | -39.0% | -73.6% | -38.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $109.43, 14% above the current price; targets range from $98.00 to $134.00; the consensus rating is “Strong buy”; expected EPS is $1.50 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Kiniksa Pharmaceuticals International’s P/E ratio?
About 73.5, based on the last twelve months of diluted earnings per share (forward P/E about 53.3).
Is Kiniksa Pharmaceuticals International stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 19% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Kiniksa Pharmaceuticals International pay a dividend?
Not currently.
Is Kiniksa Pharmaceuticals International a good stock to buy?
We do not give buy or sell advice. Kiniksa Pharmaceuticals International scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.